The United States Patent and Trademark Office (USPTO) has granted Insmed Incorporated US Patent Number 9,566,234, titled, “Systems for treating pulmonary infections,” the company said. The patent’s claims relate to the use of Insmed’s Arikayce liposomal amikacin inhalation solution for the treatment of nontuberculous mycobacteria (NTM) and other pulmonary infections.
According to Insmed, this is the seventh US patent for Arikayce use in NTM and extends patent coverage by approximately five and a half years to January 2034.
Insmed President and CEO Will Lewis commented, “This new patent significantly extends our long-term intellectual property protection for Arikayce in the US and provides us with further protection at a time when we will have potentially reached a mature point in our commercial efforts for Arikayce in NTM. We will continue to pursue additional patents in the US and other major markets worldwide to further strengthen our patent estate and enhance the value potential of Arikayce.”
Arikayce is currently in Phase 3 development for the treatment of NTM lung infections. In June 2016, Insmed announced that it had withdrawn its MAA for Arikayce for the treatment of NTM and would resubmit the application after completion of the Phase 3 study.
Read the Insmed press release.
